Clotrimazole+Lactulose.

Phase 3Small molecule

AAVVA Pharmaceuticals Ltd.

Clotrimazole+Lactulose. is one of 3 small molecule programs targeting Vaginitis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

VaginitisRecruiting

VaginitisPhase 3

Recruiting

Competition

Competitive Landscape

2 competitors in Vaginitis

#DrugCompanyPhaseTrials

Diflucan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Trolamine (biafine)

1 3

Clotrimazole+Lactulose.

AAVVA Pharmaceuticals Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaginitis1 trial

Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis

Recruiting·AAVVA Pharmaceuticals Ltd.·Phase 2/3·NCT06835361·264 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Clotrimazole+Lactulose.. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Clotrimazole+Lactulose. compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Clotrimazole+Lactulose.. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AVVA Pharmaceuticals Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAVVA Pharmaceuticals Ltd.

Clotrimazole+Lactulose.

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Vaginitis1 trial

References

Drug Info

Quick Facts

Related News